7 unknown, 2 completed, 1 not yet recruiting, 1 suspended. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Unknown 7, Completed 2, Not yet recruiting 1, Suspended 1 |
Follow icotinib: new trials by email Literature Review of icotinib trials Research Report on icotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2 Befotertinib, Icotinib - Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2 | Phase 4 | Not yet recruiting | Zhou Chengzhi | 100 | 2026-11-30 | 2026-10-28 |
| Cryotherapy Combine Icotinib for Advanced NSCLC Treatment Cryotherapy, Icotinib - Lung Neoplasms | Phase 4 | Completed | Fuda Cancer Hospital, Guangzhou | 60 | 2016-04-01 | 2020-05-27 |
| Conmana Combined With Thalidomide to Treat NSCLC Conmana, Thalidomide - NSCLC | Phase 4 | Unknown | Henan Provincial People's Hospital | 67 | 2016-03-01 | 2016-05-20 |
| High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation icotinib - NSCLC | Phase 4 | Unknown | Betta Pharmaceuticals Co., Ltd. | 240 | 2015-04-01 | 2017-07-28 |
| Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Icotinib, chemotherapy (Carboplatin and Docetaxel) - Neoplasms, Therapy-Associated | Phase 4 | Unknown | Chinese PLA General Hospital | 10 | 2014-10-01 | 2014-11-05 |
| Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Sequential Icotinib Plus Chemotherapy, Icotinib - EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 4 | Unknown | Betta Pharmaceuticals Co., Ltd. | 192 | 2014-03-01 | 2015-04-29 |
| Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Erlotinib, Gefitinib, Icotinib - Non-Small-Cell Lung Cancer | Phase 4 | Unknown | Qilu Hospital of Shandong University | 250 | 2014-01-01 | 2016-03-29 |
| Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Icotinib plus WBRT - Non-small-cell Lung Cancer | Phase 4 | Unknown | Betta Pharmaceuticals Co., Ltd. | 80 | 2013-06-01 | 2015-07-15 |
| Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Icotinib - Non-small Cell Lung Cancer | Phase 4 | Suspended | Betta Pharmaceuticals Co., Ltd. | 20 | 2013-02-01 | 2015-05-22 |
| First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients Icotinib - Non-Small Cell Lung Cancer | Phase 4 | Unknown | Betta Pharmaceuticals Co., Ltd. | 35 | 2012-07-01 | 2015-09-09 |
| Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Icotinib - Non-small Cell Lung Cancer | Phase 4 | Completed | Betta Pharmaceuticals Co., Ltd. | 32 | 2011-09-01 | 2014-02-17 |
Carcinoma, Non-Small-Cell Lung (5) · Adenocarcinoma (1) · Lung Neoplasms (1) · Neoplasms, Second Primary (1)
Betta Pharmaceuticals Co., Ltd. (6) · Chinese PLA General Hospital (1) · Fuda Cancer Hospital, Guangzhou (1) · Henan Provincial People's Hospital (1) · Qilu Hospital of Shandong University (1) · Zhou Chengzhi (1)
China (9)
Han Baohui, MD (1) · Helong Zhang, MD (1) · Hu Chengping, M.D. (1) · Lizhi Liu, M.D. (1) · Wei Zhu, MD (1) · Yang Liu, doctor (1) · Yu Li, Professor (1)